Wednesday, July 8, 2026

Drug profile · INN

avelumab

avelumab (BAVENCIO) is a programmed cell death 1 ligand 1 other. Associated with Merck KGaA, Darmstadt, Germany. Route of administration: injection. Current US regulatory status: approved.

FDA: approved EMA: approved TGA: approved PMDA: approved Antineoplastic and immunomodulating agents (L01) L01FF04
US status approved
Patents linked 6
Pipeline programs 25
News articles 1
Drug details — avelumab
US status
approved
Class
Antineoplastic and immunomodulating agents (L01)
Route
INJECTION
Patents
6
Programs
25
Data quality
0.84

Quick answer

avelumab (BAVENCIO) is a programmed cell death 1 ligand 1 other. Associated with Merck KGaA, Darmstadt, Germany. Route of administration: injection. Current US regulatory status: approved.

Key facts

INN avelumab
Brand BAVENCIO
Mechanism Programmed cell death 1 ligand 1 other
Target Programmed cell death 1 ligand 1
Therapeutic class Antineoplastic and immunomodulating agents (L01)
Route INJECTION
Formulation INJECTABLE
ATC code L01FF04

Mechanism of action

Programmed cell death 1 ligand 1 other

Primary target: Programmed cell death 1 ligand 1

Approval history

Authority Status Date
FDA approved
EMA approved
TGA approved
PMDA approved

Recent coverage

Pipeline programs

  1. Avelumab Phase 3 · Pfizer · Advanced Malignancies
  2. Avelumab Phase 3 · Serana Europe · First Line Non-Small Cell Lung Cancer
  3. B9991046 Phase 3 · First Biotech (Australia) · Cancer
  4. BT8009-230 Phase 3 · BICYCLE THERAPEUTICS · Locally advanced or metastatic urothelial cancer
  5. BT8009-230 Phase 3 · BICYCLE THERAPEUTICS · Locally advanced or metastatic urothelial cancer
  6. Bavencio 20 mg/mL concentrate for solution for infusion Phase 3 · MSD Merck Sharp · Solid Tumors
  7. Chemotherapy + avelumab followed by avelumab + talazoparib Phase 3 · Pfizer · Ovarian Cancer
  8. UC-IMM-2101 Phase 3 · Ningbo Cancer Hospital · Only patients with oncologic locally advanced or metastatic

Related & competitor drugs

  1. abiraterone acetate Antineoplastic and immunomodulating agents (L02)
  2. anagrelide Antineoplastic and immunomodulating agents (L01)
  3. apremilast Antineoplastic and immunomodulating agents (L04)
  4. arsenic trioxide Antineoplastic and immunomodulating agents (L01)
  5. axitinib Antineoplastic and immunomodulating agents (L01)
  6. azacitidine Antineoplastic and immunomodulating agents (L01)
  1. US 11534488

    Use of semaphorin-4D binding molecules for modulation of blood brain barrier permeability

    Expires Mon Dec 22 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  2. US 10800853

    Use of semaphorin-4D binding molecules for treating neurodegenerative disorders

    Expires Mon Oct 08 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  3. US 10385136

    Use of semaphorin-4D binding molecules for treating neurodegenerative disorders

    Expires Mon Aug 15 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  4. US 9790271

    Methods for increasing immunoglobulin A levels

    Expires Mon Oct 12 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  5. US 9598495

    Use of semaphorin-4D binding molecules for treating neurodegenerative disorders

    Expires Mon Mar 16 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  6. US 9249227

    Use of semaphorin-4D binding molecules for treating neurodegenerative disorders

    Expires Mon Jan 28 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is avelumab?

avelumab (BAVENCIO) is a programmed cell death 1 ligand 1 other. Associated with Merck KGaA, Darmstadt, Germany. Route of administration: injection. Current US regulatory status: approved.

What is the brand name for avelumab?

BAVENCIO is a marketed brand name for avelumab. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of avelumab?

avelumab has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.